Protagonist Therapeutics PTGX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$114.71M+11.9% | -$130.15M-383% | $45.91M-11.8% | $52.04M-7.4% | $56.19M-79.6% | ||
| $1.45M+13.1% | $1.28M+25.2% | $1.02M+14.6% | $892K+7.6% | $829K+0.4% | ||
| $46.69M+1.6% | $45.97M+3.6% | $44.37M+0.9% | $43.97M+4.7% | $42M+11.8% | ||
| —— | —— | —— | —— | —— | ||
| $1.26M-20.8% | $1.59M-9.5% | $1.76M-28.1% | $2.44M+47.3% | $1.66M+22.4% | ||
| —— | —— | —— | —— | -$399.96M-33.5% | ||
| $34.8M+52.2% | $22.86M-5.0% | $24.06M-21.0% | $30.45M+1.2% | $30.1M+16.4% | ||
| —— | —— | —— | -$187.04M-468% | -$32.92M+63.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Protagonist Therapeutics generate?
- Protagonist Therapeutics (PTGX) generated $317.6M in operating cash flow over the trailing twelve months.
- What is Protagonist Therapeutics's free cash flow?
- After $1.3M of capital expenditures, Protagonist Therapeutics's free cash flow was $316.6M over the trailing twelve months, up 364.9% year over year.
- Where does Protagonist Therapeutics's cash flow data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
